2
|
Escuin-Ordinas H, Liu Y, Sun L, Hugo W, Dimatteo R, Huang RR, Krystofinski P, Azhdam A, Lee J, Comin-Anduix B, Cochran AJ, Lo RS, Segura T, Scumpia PO, Ribas A. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. PLoS One 2021; 16:e0252597. [PMID: 34161353 PMCID: PMC8221471 DOI: 10.1371/journal.pone.0252597] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Accepted: 02/21/2021] [Indexed: 12/13/2022] Open
Abstract
Wound healing is a multi-step process to rapidly restore the barrier function. This process is often impaired in diabetic patients resulting in chronic wounds and amputation. We previously found that paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway via topical administration of the BRAF inhibitor vemurafenib accelerates wound healing by activating keratinocyte proliferation and reepithelialization pathways in healthy mice. Herein, we investigated whether this wound healing acceleration also occurs in impaired diabetic wounds and found that topical vemurafenib not only improves wound healing in a murine diabetic wound model but unexpectedly promotes hair follicle regeneration. Hair follicles expressing Sox-9 and K15 surrounded by CD34+ stroma were found in wounds of diabetic and non-diabetic mice, and their formation can be prevented by blocking downstream MEK signaling. Thus, topically applied BRAF inhibitors may accelerate wound healing, and promote the restoration of improved skin architecture in both normal and impaired wounds.
Collapse
Affiliation(s)
- Helena Escuin-Ordinas
- Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America
- * E-mail: (AR); (HEO)
| | - Yining Liu
- Department of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California, United States of America
| | - Lu Sun
- Division of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America
| | - Willy Hugo
- Division of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America
| | - Robert Dimatteo
- Department of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California, United States of America
| | - Rong Rong Huang
- Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, California, United States of America
| | - Paige Krystofinski
- Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America
| | - Ariel Azhdam
- Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America
| | - Jordan Lee
- Department of Dermatology, VA Greater Los Angeles Healthcare System-West Los Angeles, Los Angeles, California, United States of America
| | - Begoña Comin-Anduix
- Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, California, United States of America
- Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California, United States of America
| | - Alistair J. Cochran
- Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, California, United States of America
| | - Roger S. Lo
- Division of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America
- Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California, United States of America
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States of America
| | - Tatiana Segura
- Department of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California, United States of America
- Department of Biomedical Engineering, Duke University, Durham, North Carolina, United States of America
| | - Philip O. Scumpia
- Division of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America
- Department of Dermatology, VA Greater Los Angeles Healthcare System-West Los Angeles, Los Angeles, California, United States of America
| | - Antoni Ribas
- Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America
- Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, California, United States of America
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States of America
- Department of Biological Chemistry, UCLA, Los Angeles, California, United States of America
- * E-mail: (AR); (HEO)
| |
Collapse
|
3
|
Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov 2017; 7:188-201. [PMID: 27903500 PMCID: PMC5296316 DOI: 10.1158/2159-8290.cd-16-1223] [Citation(s) in RCA: 881] [Impact Index Per Article: 125.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Revised: 11/28/2016] [Accepted: 11/28/2016] [Indexed: 01/05/2023]
Abstract
Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 patients with mismatch repair-deficient colon cancer treated with PD-1 blockade. Both cases had a high mutational load but did not respond to anti-PD-1 therapy. Two out of 48 human melanoma cell lines had JAK1/2 mutations, which led to a lack of PD-L1 expression upon interferon gamma exposure mediated by an inability to signal through the interferon gamma receptor pathway. JAK1/2 loss-of-function alterations in The Cancer Genome Atlas confer adverse outcomes in patients. We propose that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy. SIGNIFICANCE A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188-201. ©2016 AACR.See related commentary by Marabelle et al., p. 128This article is highlighted in the In This Issue feature, p. 115.
Collapse
Affiliation(s)
| | - Jesse M Zaretsky
- University of California, Los Angeles (UCLA), Los Angeles, California
| | | | - Angel Garcia-Diaz
- University of California, Los Angeles (UCLA), Los Angeles, California
| | | | - Anusha Kalbasi
- University of California, Los Angeles (UCLA), Los Angeles, California
| | | | - Willy Hugo
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Salemiz Sandoval
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Davis Y Torrejon
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Nicolaos Palaskas
- University of California, Los Angeles (UCLA), Los Angeles, California
| | | | - Giulia Parisi
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Ariel Azhdam
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Bartosz Chmielowski
- University of California, Los Angeles (UCLA), Los Angeles, California
- Jonsson Comprehensive Cancer Center, Los Angeles, California
| | - Grace Cherry
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Elizabeth Seja
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Beata Berent-Maoz
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - I Peter Shintaku
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Dung T Le
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
| | - Drew M Pardoll
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
| | - Luis A Diaz
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
| | - Paul C Tumeh
- University of California, Los Angeles (UCLA), Los Angeles, California
| | - Thomas G Graeber
- University of California, Los Angeles (UCLA), Los Angeles, California
- Jonsson Comprehensive Cancer Center, Los Angeles, California
| | - Roger S Lo
- University of California, Los Angeles (UCLA), Los Angeles, California
- Jonsson Comprehensive Cancer Center, Los Angeles, California
| | - Begoña Comin-Anduix
- University of California, Los Angeles (UCLA), Los Angeles, California
- Jonsson Comprehensive Cancer Center, Los Angeles, California
| | - Antoni Ribas
- University of California, Los Angeles (UCLA), Los Angeles, California.
- Jonsson Comprehensive Cancer Center, Los Angeles, California
| |
Collapse
|